Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1954 3
1955 2
1956 2
1957 4
1958 3
1959 1
1960 5
1961 3
1962 13
1963 11
1964 14
1965 17
1966 26
1967 34
1968 19
1969 20
1970 33
1971 28
1972 24
1973 23
1974 27
1975 37
1976 34
1977 35
1978 31
1979 51
1980 57
1981 70
1982 109
1983 84
1984 110
1985 131
1986 144
1987 129
1988 166
1989 146
1990 147
1991 166
1992 216
1993 192
1994 214
1995 227
1996 249
1997 296
1998 304
1999 310
2000 309
2001 342
2002 340
2003 386
2004 404
2005 372
2006 341
2007 369
2008 389
2009 404
2010 442
2011 481
2012 500
2013 516
2014 486
2015 522
2016 574
2017 625
2018 611
2019 624
2020 646
2021 730
2022 668
2023 686
2024 511
2025 4

Text availability

Article attribute

Article type

Publication date

Search Results

14,885 results

Results by year

Filters applied: . Clear all
Page 1
Integrated proteomics identifies p62-dependent selective autophagy of the supramolecular vault complex.
Kurusu R, Fujimoto Y, Morishita H, Noshiro D, Takada S, Yamano K, Tanaka H, Arai R, Kageyama S, Funakoshi T, Komatsu-Hirota S, Taka H, Kazuno S, Miura Y, Koike M, Wakai T, Waguri S, Noda NN, Komatsu M. Kurusu R, et al. Among authors: tanaka h. Dev Cell. 2023 Jul 10;58(13):1189-1205.e11. doi: 10.1016/j.devcel.2023.04.015. Epub 2023 May 15. Dev Cell. 2023. PMID: 37192622 Free article.
Ready-to-Use-Type Lyophilized Lipid Nanoparticle Formulation for the Postencapsulation of Messenger RNA.
Tanaka H, Hagiwara S, Shirane D, Yamakawa T, Sato Y, Matsumoto C, Ishizaki K, Hishinuma M, Chida K, Sasaki K, Yonemochi E, Ueda K, Higashi K, Moribe K, Tadokoro T, Maenaka K, Taneichi S, Nakai Y, Tange K, Sakurai Y, Akita H. Tanaka H, et al. ACS Nano. 2023 Feb 14;17(3):2588-2601. doi: 10.1021/acsnano.2c10501. Epub 2023 Jan 31. ACS Nano. 2023. PMID: 36719091
Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity.
Edahiro R, Shirai Y, Takeshima Y, Sakakibara S, Yamaguchi Y, Murakami T, Morita T, Kato Y, Liu YC, Motooka D, Naito Y, Takuwa A, Sugihara F, Tanaka K, Wing JB, Sonehara K, Tomofuji Y; Japan COVID-19 Task Force; Namkoong H, Tanaka H, Lee H, Fukunaga K, Hirata H, Takeda Y, Okuzaki D, Kumanogoh A, Okada Y. Edahiro R, et al. Among authors: tanaka h. Nat Genet. 2023 May;55(5):753-767. doi: 10.1038/s41588-023-01375-1. Epub 2023 Apr 24. Nat Genet. 2023. PMID: 37095364 Free PMC article.
S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells.
Nagira Y, Nagira M, Nagai R, Nogami W, Hirata M, Ueyama A, Yoshida T, Yoshikawa M, Shinonome S, Yoshida H, Haruna M, Miwa H, Chatani N, Ohkura N, Wada H, Tanaka H. Nagira Y, et al. Among authors: tanaka h. Mol Cancer Ther. 2023 Sep 5;22(9):1063-1072. doi: 10.1158/1535-7163.MCT-22-0570. Mol Cancer Ther. 2023. PMID: 37420296 Free PMC article.
An Ionizable Lipid Material with a Vitamin E Scaffold as an mRNA Vaccine Platform for Efficient Cytotoxic T Cell Responses.
Oyama R, Ishigame H, Tanaka H, Tateshita N, Itazawa M, Imai R, Nishiumi N, Kishikawa JI, Kato T, Anindita J, Nishikawa Y, Maeki M, Tokeshi M, Tange K, Nakai Y, Sakurai Y, Okada T, Akita H. Oyama R, et al. Among authors: tanaka h. ACS Nano. 2023 Oct 10;17(19):18758-18774. doi: 10.1021/acsnano.3c02251. Epub 2023 Sep 26. ACS Nano. 2023. PMID: 37814788 Free PMC article.
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
Zhou C, Srivastava MK, Xu H, Felip E, Wakelee H, Altorki N, Reck M, Liersch R, Kryzhanivska A, Oizumi S, Tanaka H, Hamm J, McCune SL, Bennett E, Gitlitz B, McNally V, Ballinger M, McCleland M, Zou W, Das Thakur M, Novello S. Zhou C, et al. Among authors: tanaka h. J Immunother Cancer. 2023 Oct;11(10):e007047. doi: 10.1136/jitc-2023-007047. J Immunother Cancer. 2023. PMID: 37903590 Free PMC article. Clinical Trial.
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Nishio M, Ohe Y, Ikeda S, Yokoyama T, Hayashi H, Fukuhara T, Sato Y, Tanaka H, Hotta K, Sugawara S, Daga H, Okamoto I, Kasahara K, Naito T, Li L, Gupta RG, Bushong J, Mizutani H. Nishio M, et al. Among authors: tanaka h. Int J Clin Oncol. 2023 Oct;28(10):1354-1368. doi: 10.1007/s10147-023-02390-2. Epub 2023 Aug 7. Int J Clin Oncol. 2023. PMID: 37548831 Free PMC article. Clinical Trial.
14,885 results
You have reached the last available page of results. Please see the User Guide for more information.